This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Nebilet, nebivolol
Description: Nebivolol is a lipophilic beta1-blocker. It is devoid of intrinsic sympathomimetic or membrane stabilising activity but appears to have nitric oxide-mediated vasodilatory effects.
Mylan and Bertek
In April 2001, Mylan announced that Bertek Pharmaceuticals, the branded products division of Mylan, obtained exclusive U.S. and Canadian rights for nebivolol from Janssen Pharmaceutical N.V.
Mylan and Forest
In January 2006, Mylan Laboratories and Forest Laboratories entered into an agreement for the commercialization, development and distribution of nebivolol in the United States and Canada. Under the terms of the agreement, Forest will make an upfront payment to Mylan of $75 million as well as potential future milestone payments. In addition, Mylan will also receive royalty payments based on nebivolol sales. Forest will assume all nebivolol development expenses for current and future development programs. Forest will be responsible for all sales and marketing expenses and Mylan has retained an option to co-promote the product in the future.
In February 2008, Forest Laboratories announced that it and Mylan have amended their...See full deal structure in Biomedtracker
Partners: Mylan Inc. The Menarini Group
Pink Sheet Bystolic correction
Additional information available to subscribers only: